##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 86 Download : 68

##plugins.themes.academic_pro.article.main##

Abstract

Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment Neovascular (“wet”) form of age-related macular degeneration (nAMD) is the leading cause of irreversible visual impairment in people over the age of 60 in economically advanced countries. Until recent time, the diagnosis of nAMD was actually a verdict for the patient in terms of visual prognosis - it was clear to both doctors and patients that a decrease in central vision was inevitable, the only question was the timing of maintaining functionally useful vision of the affected eye, as well as the timing of damage to the fellow eye and disability of the patient.

Keywords

patient degeneration prevalent leading

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Abdullaev Sh.O, Abdullaev A.K, & Mamatkhujaeva G.N. (2022). Therapy for neovascular age-related macular degeneration: updated review. Texas Journal of Medical Science, 10, 19–22. https://doi.org/10.62480/tjms.2022.vol10.pp19-22
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Rosenfeld P.J., Brown D.M., Heier J.S. et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. DOI: 10.1056/NEJMoa054481.
  2. Brown D.M., Kaiser P.K., Michels M. et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. DOI: 10.1056/NEJMoa062655.
  3. Heier J.S., Brown D.M., Chong V. et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012;119(12):2537–2548.
  4. Zhang K., Zhang L., Weinreb R.N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucomaNat Rev Drug Discov. 2012;11(7):541–559.
  5. Rofagha S., Bhisitkul R.B., Boyer D.S. et al. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299.
  6. Rasmussen A., Bloch S.B., Fuchs J. et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:2630–2636.
  7. Amoaku W.M., Chakravarthy U., Gale R. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29:721–731. DOI: 10.1038/eye.2015.48.
  8. Lanzetta P., Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–1273. DOI: 10.1007/s00417-017-3647-4.
  9. Fayzrakhmanov R.R. Prescribing regimens for anti-VEGF drugs in the treatment of neovascular age-related macular degeneration. Bulletin of ophthalmology. 2018;134(6):107–115. [Fayzrakhmanov R.R. Regimens for prescribing anti-VEGF drugs in therapy neovascular age-related macular degeneration. Bulletin of Ophthalmology. 2018;134(6):107–115. DOI: 10.17116/OFTALMA2018134061105 (in Russ.)].
  10. Ohji M., Takahashi K., Okada A.A. et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR. Adv Ther. 2020;37(3):1173–1187. DOI: 10.1007/s12325-020-01236-x.
  11. Fauser S., Muether P.S. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;0:1–5. DOI: 10.1136/bjophthalmol-2015-308264.